MedFactory receives US FDA approval to add medium-dose patient group to Phase 2 trial of Vatiquinone (Baptiserp)
Predicted impact: Low
Mid-dose cohort FDA approval for Phase 2 trial already reported in recent days.
MedPacto메드팩토
235980 · KOSDAQ · ₩235980 · 메드팩토
₩3,050▲ ₩80 (2.69%)End-of-day · Oct 30, 2026 · End-of-day prices.
MedFactory Adds Mid-Dose Cohort to Phase 2 Trial of Vactosertib for Osteosarcoma… Approved by U.S. FDA
Predicted impact: Low
Trial cohort addition with FDA approval, early-stage and no revenue size given.
Also known as: MedPacto / 메드팩토 / 235980 / KRX:235980
Source: KRX statistical information